{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:14:06Z","timestamp":1792271646457,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100019353","name":"Belgian Health Care Knowledge Centre","doi-asserted-by":"publisher","award":["KCE_HSR 2020-50"],"award-info":[{"award-number":["KCE_HSR 2020-50"]}],"id":[{"id":"10.13039\/501100019353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40258-025-00956-x","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T10:55:36Z","timestamp":1745060136000},"page":"613-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Compulsory Licensing as an Instrument to Tackle High Medicine Prices: A Realist Review of Industrial and Health Consequences"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-2005","authenticated-orcid":false,"given":"Steven","family":"Simoens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Van Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liese","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Luyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"956_CR1","doi-asserted-by":"crossref","unstructured":"Van Zimmeren E, Minssen T, Paemen L, et al. Compulsory licensing for expensive medicines. KCE Reports 356 Brussels: Belgian Health Care Knowledge Centre (KCE); 2022. Available from: https:\/\/kce.fgov.be\/en\/compulsory-licensing-for-expensive-medicines. Accessed 23 Apr 2024.","DOI":"10.57598\/R356C"},{"key":"956_CR2","unstructured":"World Trade Organization. Agreement on Trade-Related Aspects of Intellectual Property Rights 1994. Available from: https:\/\/www.wto.org\/english\/docs_e\/legal_e\/27-trips_01_e.htm. Accessed 23 Apr 2024."},{"issue":"2","key":"956_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/dewb.12124.English","volume":"17","author":"S Guennif","year":"2017","unstructured":"Guennif S. Evaluating the usefulness of compulsory licensing in developing countries: a comparative study of thai and brazilian experiences regarding access to aids treatments [Article]. Dev World Bioeth. 2017;17(2):90\u20139. https:\/\/doi.org\/10.1111\/dewb.12124.English.","journal-title":"Dev World Bioeth"},{"issue":"1","key":"956_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/1468-0009.12557","volume":"100","author":"L Qunaj","year":"2022","unstructured":"Qunaj L, Kaltenboeck A, Bach PB. Compulsory licensing of pharmaceuticals in high-income countries: a comparative analysis. Milbank Q. 2022;100(1):284\u2013313. https:\/\/doi.org\/10.1111\/1468-0009.12557. (PubMedPMID:35257415;PubMedCentralPMCID:PMCPMC8932629).","journal-title":"Milbank Q"},{"key":"956_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-005518","author":"K Perehudoff","year":"2021","unstructured":"Perehudoff K, t Hoen E, Boulet P. Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too. BMJ Glob Health. 2021. https:\/\/doi.org\/10.1136\/bmjgh-2021-005518. (PubMed PMID: 33827793; PubMed Central PMCID: PMCPMC8031020).","journal-title":"BMJ Glob Health"},{"key":"956_CR6","unstructured":"European Commission. COM(2023)224 - Proposal for a regulation of the European Parliament and of the Council on compulsory licensing for crisis management and amending Regulation (EC) 816\/2006 2023. Available from: https:\/\/single-market-economy.ec.europa.eu\/publications\/com2023224-proposal-regulation-compulsory-licensing-crisis-management_en. Accessed 23 Apr 2024."},{"key":"956_CR7","unstructured":"de Jong A. Persoonlijke beschouwing over de inzet van de dwanglicenties bij hoge prijzen van medicijnen (personal consideration of the use of compulsory licences for high medicine prices) Den Haag: ABDTOPConsult; 2020. Available from: https:\/\/www.rijksoverheid.nl\/documenten\/rapporten\/2020\/06\/16\/persoonlijke-beschouwing-over-de-inzet-van-de-dwanglicenties-bij-hoge-prijzen-van-medicijnen. Accessed 23 Apr 2024."},{"issue":"1","key":"956_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1163\/15718093-BJA10004.English","volume":"28","author":"A den Exter","year":"2020","unstructured":"den Exter A. Fighting excessive pharmaceutical prices: evaluating the options [Article]. Eur J Health Law. 2020;28(1):68\u201380. https:\/\/doi.org\/10.1163\/15718093-BJA10004.English.","journal-title":"Eur J Health Law"},{"key":"956_CR9","unstructured":"Pawson R, Greenhalgh T, Harvey G, et al. Realist Synthesis - an Introduction. ESRC Working Paper Series. London: Economic and Social Research Council; 2004."},{"issue":"Suppl 1","key":"956_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1258\/1355819054308530","volume":"10","author":"R Pawson","year":"2005","unstructured":"Pawson R, Greenhalgh T, Harvey G, et al. Realist review\u2013a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy. 2005;10(Suppl 1):21\u201334. https:\/\/doi.org\/10.1258\/1355819054308530. (PubMed PMID: 16053581).","journal-title":"J Health Serv Res Policy"},{"issue":"11","key":"956_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1741-7015-11-21","volume":"29","author":"G Wong","year":"2013","unstructured":"Wong G, Greenhalgh T, Westhorp G, et al. RAMESES publication standards: realist syntheses. BMC Med. 2013;29(11):21. https:\/\/doi.org\/10.1186\/1741-7015-11-21. (PubMedPMID:23360677;PubMedCentralPMCID:PMCPMC3558331).","journal-title":"BMC Med"},{"issue":"3","key":"956_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2471\/blt.13.128413","volume":"92","author":"OA Owoeye","year":"2014","unstructured":"Owoeye OA. Compulsory patent licensing and local drug manufacturing capacity in Africa. Bull World Health Organ. 2014;92(3):214\u20139. https:\/\/doi.org\/10.2471\/blt.13.128413. (PubMedPMID:24700981 PubMedCentralPMCID:PMCPMC3949597.eng).","journal-title":"Bull World Health Organ"},{"key":"956_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2098","volume":"365","author":"G Ooms","year":"2019","unstructured":"Ooms G, Hanefeld J. Threat of compulsory licences could increase access to essential medicines. BMJ. 2019;365: l2098. https:\/\/doi.org\/10.1136\/bmj.l2098.","journal-title":"BMJ"},{"key":"956_CR14","unstructured":"Urias E. Improving access to HIV\/AIDS treatment in Brazil. When are compulsory licenses effective in price negotiations? 2015. Available from: https:\/\/cris.maastrichtuniversity.nl\/en\/publications\/improving-access-to-hivaids-treatment-in-brazil-when-are-compulso. Accessed 23 Apr 2024."},{"issue":"1","key":"956_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10198-013-0556-2.PubMedPMID:24408475;eng","volume":"16","author":"C Stavropoulou","year":"2015","unstructured":"Stavropoulou C, Valletti T. Compulsory licensing and access to drugs. Eur J Health Econ. 2015;16(1):83\u201394. https:\/\/doi.org\/10.1007\/s10198-013-0556-2.PubMedPMID:24408475;eng.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"956_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/0098858815622193.PubMedPMID:26863852;eng","volume":"41","author":"J Brodsky","year":"2015","unstructured":"Brodsky J. The health of EBAY: the impact of EBAY on the future of TRIPS-like pharmaceutical compulsory licenses in the United States. Am J Law Med. 2015;41(4):656\u201379. https:\/\/doi.org\/10.1177\/0098858815622193.PubMedPMID:26863852;eng.","journal-title":"Am J Law Med"},{"issue":"1","key":"956_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1257\/aer.102.1.396","volume":"102","author":"P Moser","year":"2012","unstructured":"Moser P, Voena A. Compulsory licensing: evidence from the trading with the enemy act [Article]. Am Econ Rev. 2012;102(1):396\u2013427. https:\/\/doi.org\/10.1257\/aer.102.1.396. (PubMed PMID: 71360822).","journal-title":"Am Econ Rev"},{"key":"956_CR18","unstructured":"Lalitha N. A review of the pharmaceutical industry of Canada. Working Paper Series. Gota, Ahmedabad, Gujarat Institute of Development Research. 2004."},{"issue":"6","key":"956_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1747-1796.2000.tb00158.x","volume":"3","author":"RP Rozek","year":"2000","unstructured":"Rozek RP. The effects of compulsory licensing on innovation and access to health care. Journal of World Intellectual Property. 2000;3(6):889\u2013918.","journal-title":"Journal of World Intellectual Property."},{"issue":"3","key":"956_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/mde.4090140305","volume":"14","author":"DM Shapiro","year":"1993","unstructured":"Shapiro DM, Switzer LN. The stock market response to changing drug patent legislation: the case of compulsory licensing in Canada. Manag Decis Econ. 1993;14(3):247\u201359.","journal-title":"Manag Decis Econ"},{"key":"956_CR21","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.respol.2018.05.008","volume":"47","author":"SV Ramani","year":"2018","unstructured":"Ramani SV, Urias E. When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil. Res Policy. 2018;47:1538\u201352.","journal-title":"Res Policy"},{"issue":"3","key":"956_CR22","first-page":"254","volume":"3","author":"MZ Abbas","year":"2013","unstructured":"Abbas MZ. Pros and cons of compulsory licensing: an analysis of arguments. Int J Soc Sci Hum. 2013;3(3):254\u20138.","journal-title":"Int J Soc Sci Hum"},{"issue":"1","key":"956_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001154","volume":"9","author":"R Beall","year":"2012","unstructured":"Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis. PLoS Med. 2012;9(1): e1001154.","journal-title":"PLoS Med"},{"issue":"1","key":"956_CR24","doi-asserted-by":"publisher","first-page":"010358","DOI":"10.7189\/jogh.10.010358","volume":"10","author":"H Wong","year":"2020","unstructured":"Wong H. The case for compulsory licensing during COVID-19. J Glob Health. 2020;10(1):010358. https:\/\/doi.org\/10.7189\/jogh.10.010358. (PubMed PMID: 32509289; PubMed Central PMCID: PMCPMC7242884 (available upon request) and declares no conflicts of interest. eng).","journal-title":"J Glob Health"},{"issue":"1","key":"956_CR25","first-page":"87","volume":"25","author":"VS Vastano","year":"2001","unstructured":"Vastano VS. Compulsory licensing of pharmaceuticals under TRIPS: what standard of compensation. Hastings Int Comp Law Rev. 2001;25(1):87\u2013110.","journal-title":"Hastings Int Comp Law Rev"},{"issue":"2","key":"956_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1748-720X.2009.00367.x","volume":"37","author":"KM Lybecker","year":"2009","unstructured":"Lybecker KM, Fowler E. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules. J Law Med Ethics. 2009;37(2):222\u201339. https:\/\/doi.org\/10.1111\/j.1748-720X.2009.00367.x. (PubMed PMID: 19493068; eng).","journal-title":"J Law Med Ethics"},{"key":"956_CR27","unstructured":"Financial Times. How Covid has raised the profiles and fortunes of India's pharma entrepreneurs. Financial Times. 2021."},{"key":"956_CR28","unstructured":"Correa CM. The use of compulsory licenses in Latin America 2013. Available from: https:\/\/www.southcentre.int\/question\/the-use-of-compulsory-licenses-in-latin-america\/. Accessed 23 Apr 2024."},{"key":"956_CR29","volume-title":"Pharmaceutical innovation, incremental patenting and compulsory licensing","author":"CM Correa","year":"2013","unstructured":"Correa CM. Pharmaceutical innovation, incremental patenting and compulsory licensing. Geneva: South Centre; 2013."},{"issue":"1","key":"956_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/02601079x07001900103","volume":"19","author":"F Cugno","year":"2007","unstructured":"Cugno F, Ottoz E. Static efficiency of compulsory licensing: the role of limit pricing. J Interdiscip Econ. 2007;19(1):19\u201333. https:\/\/doi.org\/10.1177\/02601079x07001900103.","journal-title":"J Interdiscip Econ"},{"key":"956_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.socscimed.2015.04.023","volume":"135","author":"SV Ramani","year":"2015","unstructured":"Ramani SV, Urias E. Access to critical medicines: when are compulsory licenses effective in price negotiations? Soc Sci Med. 2015;135:75\u201383. https:\/\/doi.org\/10.1016\/j.socscimed.2015.04.023. (PubMedPMID:25957163;eng).","journal-title":"Soc Sci Med"},{"issue":"6","key":"956_CR32","doi-asserted-by":"publisher","first-page":"1-15","DOI":"10.1007\/BF03405239","volume":"97","author":"JC Cohen","year":"2006","unstructured":"Cohen JC. Expanding drug access in Brazil: Lessons for Latin America and Canada [Article]. Can J Public Health. 2006;97(6):1-15\u20131-18 (English).","journal-title":"Can J Public Health"},{"key":"956_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-3-12","author":"JC Cohen-Kohler","year":"2007","unstructured":"Cohen-Kohler JC, Esmail LC, Cosio A. Canada\u2019s implementation of the Paragraph 6 Decision: Is it sustainable public policy? [Article]. Glob Health. 2007. https:\/\/doi.org\/10.1186\/1744-8603-3-12. (English).","journal-title":"Glob Health"},{"issue":"2\u20133","key":"956_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/009885880903500205.PubMedPMID:19697752;eng","volume":"35","author":"P Maybarduk","year":"2009","unstructured":"Maybarduk P, Rimmington S. Compulsory licenses: a tool to improve global access to the HPV vaccine? Am J Law Med. 2009;35(2\u20133):323\u201350. https:\/\/doi.org\/10.1177\/009885880903500205.PubMedPMID:19697752;eng.","journal-title":"Am J Law Med"},{"issue":"3","key":"956_CR35","first-page":"295","volume":"34","author":"AM Fisch","year":"1994","unstructured":"Fisch AM. Compulsory licensing of pharmaceutical patents: an unreasonable solution to an unfortunate problem. Jurimet J. 1994;34(3):295\u2013316.","journal-title":"Jurimet J"},{"issue":"4","key":"956_CR36","first-page":"711","volume":"58","author":"A Gillat","year":"2003","unstructured":"Gillat A. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry. Food Drug Law J. 2003;58(4):711\u201340 (PubMed PMID: 15027457; eng).","journal-title":"Food Drug Law J"},{"issue":"2","key":"956_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1748-720X.2009.00366.x","volume":"37","author":"RC Bird","year":"2009","unstructured":"Bird RC. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects. J Law Med Ethics. 2009;37(2):209\u201321. https:\/\/doi.org\/10.1111\/j.1748-720X.2009.00366.x. (PubMed PMID: 19493067; eng).","journal-title":"J Law Med Ethics"},{"issue":"2\/3","key":"956_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1542-4774.2010.tb00506.x","volume":"8","author":"PK Goldberg","year":"2010","unstructured":"Goldberg PK. Alfred Marshall lecture intellectual property rights protection in developing countries: the case of pharmaceuticals [Article]. J Eur Econ Assoc. 2010;8(2\/3):326\u201353. https:\/\/doi.org\/10.1111\/j.1542-4774.2010.tb00506.x. (PubMed PMID: 49118304).","journal-title":"J Eur Econ Assoc"},{"key":"956_CR39","volume-title":"International price negotiations under the threat of compulsory licensing","author":"EW Bond","year":"2014","unstructured":"Bond EW, Saggi K. International price negotiations under the threat of compulsory licensing. Department of Economics, Vanderbilt University; 2014."},{"key":"956_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhealeco.2015.09.001","volume":"44","author":"C Chatterjee","year":"2015","unstructured":"Chatterjee C, Kubo K, Pingali V. The consumer welfare implications of governmental policies and firm strategy in markets for medicines. J Health Econ. 2015;44:255\u201373. https:\/\/doi.org\/10.1016\/j.jhealeco.2015.09.001. (PubMedPMID:26581076;eng).","journal-title":"J Health Econ"},{"key":"956_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.geb.2018.12.003","volume":"114","author":"EW Bond","year":"2019","unstructured":"Bond EW, Samuelson L. Bargaining with private information and the option of a compulsory license. Games Econ Behav. 2019;114:83\u2013100. https:\/\/doi.org\/10.1016\/j.geb.2018.12.003.","journal-title":"Games Econ Behav"},{"issue":"2","key":"956_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17441690903575255","volume":"6","author":"V Kuek","year":"2011","unstructured":"Kuek V, Phillips K, Kohler JC. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand. Glob Public Health. 2011;6(2):111\u201324. https:\/\/doi.org\/10.1080\/17441690903575255. (PubMedPMID:20234967;eng).","journal-title":"Glob Public Health"},{"issue":"3","key":"956_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1025384819575","volume":"3","author":"PM Danzon","year":"2003","unstructured":"Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003;3(3):183\u2013205. https:\/\/doi.org\/10.1023\/A:1025384819575.","journal-title":"Int J Health Care Finance Econ"},{"issue":"4","key":"956_CR44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/jiel\/5.4.849","volume":"5","author":"H Grabowski","year":"2002","unstructured":"Grabowski H. Patents, innovation and access to new pharmaceuticals. J Int Econ Law. 2002;5(4):849\u201360.","journal-title":"J Int Econ Law"},{"key":"956_CR45","doi-asserted-by":"crossref","unstructured":"McManis CR, Contreras JL. Compulsory Licensing of Intellectual Property: A Viable Policy Lever for Promoting Access to Critical Technologies? In: Ghidini G, Peritz RJR, Ricolfi M, editors. TRIPS and Developing Countries \u2013 Towards a New World Order?: American University, WCL Research Paper No. 2014-16; 2014.","DOI":"10.4337\/9781849804943.00009"},{"key":"956_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jdeveco.2017.01.002","volume":"126","author":"J Baten","year":"2017","unstructured":"Baten J, Bianchi N, Moser P. Compulsory licensing and innovation\u2014historical evidence from German patents after WWI. J Dev Econ. 2017;126:231\u201342. https:\/\/doi.org\/10.1016\/j.jdeveco.2017.01.002.","journal-title":"J Dev Econ"},{"key":"956_CR47","volume-title":"The economic effects of compulsory patent licensing. Center for the Study of Financial Institutions","author":"FM Scherer","year":"1977","unstructured":"Scherer FM. The economic effects of compulsory patent licensing. Center for the Study of Financial Institutions. New York: New York University Monograph Series in Finance and Economics; 1977."},{"issue":"3","key":"956_CR48","first-page":"853","volume":"18","author":"C Chien","year":"2003","unstructured":"Chien C. Cheap drugs at what price to innovation: does the compulsory licensing of pharmaceuticals hurt innovation? [Article]. Berkeley Technol Law J. 2003;18(3):853\u2013907 (PubMed PMID: 11348767).","journal-title":"Berkeley Technol Law J"},{"issue":"610","key":"956_CR49","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ecoj.12434","volume":"128","author":"EW Bond","year":"2018","unstructured":"Bond EW, Saggi K. Compulsory licensing and patent protection: a North-South Perspective [Article]. Econ J. 2018;128(610):1157\u201379. https:\/\/doi.org\/10.1111\/ecoj.12434. (PubMed PMID: 129512173).","journal-title":"Econ J"},{"key":"956_CR50","volume-title":"Using compulsory licenses to access pharmaceuticals: a cross case analysis on outcomes","author":"NG Cherian","year":"2016","unstructured":"Cherian NG. Using compulsory licenses to access pharmaceuticals: a cross case analysis on outcomes. Oslo: University of Oslo; 2016."},{"key":"956_CR51","first-page":"438","volume-title":"Compulsory licensing: practical experiences and ways forward. MPI Studies on Intellectual Property and Competition Law 22","author":"Y Goyal","year":"2015","unstructured":"Goyal Y. Economic and Procedural Constraints of Compulsory Licences for Medicines. In: Hilty RM, Liu KC, editors. Compulsory licensing: practical experiences and ways forward. MPI Studies on Intellectual Property and Competition Law 22. Berlin: Springer-Verlag; 2015. p. 438\u201358."},{"key":"956_CR52","unstructured":"Health Intervention and Technology Assessment Program (HITAP). Assessing the Implications of Thailand\u2019s Government Use Licenses issued in 2006-2008 2009. Available from: https:\/\/www.hitap.net\/en\/research\/17635. Accessed 23 Apr 2024."},{"key":"956_CR53","unstructured":"Rudyk I. The License of Right, Compulsory Licensing and the Value of Exclusivity. In: LMU, editor. Discussion paper No. 4152012."},{"issue":"2","key":"956_CR54","first-page":"157","volume":"4","author":"C Antonelli","year":"2013","unstructured":"Antonelli C. Compulsory Licensing: The Foundations of an Institutional Innovation. The WIPO Journal. 2013;4(2):157\u201374.","journal-title":"The WIPO Journal."},{"issue":"23","key":"956_CR55","doi-asserted-by":"publisher","first-page":"12749","DOI":"10.1073\/pnas.93.23.12749.English","volume":"93","author":"RJ Gilbert","year":"1996","unstructured":"Gilbert RJ, Shapiro C. An economic analysis of unilateral refusals to license intellectual property [Article]. Proc Natl Acad Sci USA. 1996;93(23):12749\u201355. https:\/\/doi.org\/10.1073\/pnas.93.23.12749.English.","journal-title":"Proc Natl Acad Sci USA"},{"key":"956_CR56","doi-asserted-by":"crossref","unstructured":"Shastitko A, Kurdin A. Incentives for process innovations under discrete structural alternatives of competition policy. Voprosy Economiki. 2016;4:1\u201340.","DOI":"10.32609\/0042-8736-2016-4-56-85"},{"key":"956_CR57","unstructured":"Antonelli C. Compulosry Licensing: the foundations of an institutional innovation. In: Turin Uo, editor. Turin2012."},{"issue":"3","key":"956_CR58","first-page":"619","volume":"24","author":"F Fine","year":"2004","unstructured":"Fine F. European community compulsory licensing policy: heresy versus common sense [Article]. Northwestern J Int Law Bus. 2004;24(3):619\u201346 (PubMed PMID: 14147029).","journal-title":"Northwestern J Int Law Bus"},{"issue":"4","key":"956_CR59","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2190\/4MA6-53E3-LE1X-C1YY","volume":"29","author":"P Bond","year":"1999","unstructured":"Bond P. Globalization, pharmaceutical pricing, and South African health policy: managing confrontation with U.S. firms and politicians [Review]. Int J Health Serv. 1999;29(4):765\u201392. https:\/\/doi.org\/10.2190\/4MA6-53E3-LE1X-C1YY. (English).","journal-title":"Int J Health Serv"},{"key":"956_CR60","first-page":"193","volume":"1","author":"TC Bailey","year":"2001","unstructured":"Bailey TC. Innovation and access: the role of compulsory licensing in the development and distribution of hiv\/aids drugs. Univ Ill J Law Technol Policy. 2001;1:193\u2013218.","journal-title":"Univ Ill J Law Technol Policy"},{"key":"956_CR61","unstructured":"Phueksuwan T. Compulsory licensing policy implementation in Thailand 2014. Available from: http:\/\/libdcms.nida.ac.th\/thesis6\/2014\/b185150.pdf. Accessed 23 Apr 2024."},{"issue":"2","key":"956_CR62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1748-720X.2009.00365.x","volume":"37","author":"S Flynn","year":"2009","unstructured":"Flynn S, Hollis A, Palmedo M. An economic justification for open access to essential medicine patents in developing countries. J Law Med Ethics. 2009;37(2):184\u2013208. https:\/\/doi.org\/10.1111\/j.1748-720X.2009.00365.x. (PubMed PMID: 19493066; eng).","journal-title":"J Law Med Ethics"},{"issue":"2","key":"956_CR63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1748-720X.2009.00369.x","volume":"37","author":"JH Reichman","year":"2009","unstructured":"Reichman JH. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options. J Law Med Ethics. 2009;37(2):247\u201363. https:\/\/doi.org\/10.1111\/j.1748-720X.2009.00369.x. (PubMed PMID: 19493070; PubMed Central PMCID: PMCPMC2893582. eng).","journal-title":"J Law Med Ethics"},{"key":"956_CR64","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1057\/s42214-020-00068-4","volume":"3","author":"E Urias","year":"2020","unstructured":"Urias E, Ramani SV. Access to medicines after TRIPS: is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence. J Int Bus Policy. 2020;3:367\u201384.","journal-title":"J Int Bus Policy."},{"issue":"8","key":"956_CR65","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/13543776.2019.1643323.PubMedPMID:31298053;eng","volume":"29","author":"E Ortiz-Prado","year":"2019","unstructured":"Ortiz-Prado E, Cevallos-Sierra G, Teran E, et al. Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience. Expert Opin Ther Pat. 2019;29(8):653\u201362. https:\/\/doi.org\/10.1080\/13543776.2019.1643323.PubMedPMID:31298053;eng.","journal-title":"Expert Opin Ther Pat"},{"key":"956_CR66","unstructured":"Seifert J. Compulsory Licensing, Innovation and Welfare. Beitr\u00e4ge zur Jahrestagung des Vereins f\u00fcr Socialpolitik 2013; Wettbewerbspolitik und Regulierung in einer globalen Wirtschaftsordnung - Session: Oligopoly, No. G14-V32013."},{"issue":"1","key":"956_CR67","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.infoecopol.2003.09.002","volume":"16","author":"R Aoki","year":"2004","unstructured":"Aoki R, Small J. Compulsory licensing of technology and the essential facilities doctrine. Inform Econ Policy. 2004;16(1):13\u201329. https:\/\/doi.org\/10.1016\/j.infoecopol.2003.09.002.","journal-title":"Inform Econ Policy."},{"issue":"2","key":"956_CR68","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1257\/jel.20161327","volume":"56","author":"D Lakdawalla","year":"2018","unstructured":"Lakdawalla D. Economics of the pharmaceutical industry. J Econ Lit. 2018;56(2):397\u2013449.","journal-title":"J Econ Lit"},{"key":"956_CR69","volume-title":"The failure of compulsory licensing of pharmaceuticals in least developed countries","author":"S Brebeck","year":"2014","unstructured":"Brebeck S. The failure of compulsory licensing of pharmaceuticals in least developed countries. Essen: University of Duisburg-Essen; 2014."},{"key":"956_CR70","first-page":"166","volume-title":"Compulsory licensing: practical experiences and ways forward. MPI Studies on Intellectual Property and Competition Law 22","author":"X Lin","year":"2015","unstructured":"Lin X. Prior negotiation and remuneration for patent compulsory licensing: practice, problem, and proposal. In: Hilty RM, Liu KC, editors. Compulsory licensing: practical experiences and ways forward. MPI Studies on Intellectual Property and Competition Law 22. Berlin: Springer-Verlag; 2015. p. 166\u201390."},{"issue":"4","key":"956_CR71","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/jiel\/jgn035","volume":"11","author":"A Taubman","year":"2008","unstructured":"Taubman A. Rethinking TRIPS: \u2019Adequate Remuneration\u2019 for non-voluntary patent licensing. J Int Econ Law. 2008;11(4):927\u201370.","journal-title":"J Int Econ Law"},{"key":"956_CR72","first-page":"1","volume":"Special Edition","author":"E V\u00e4lim\u00e4ki","year":"2011","unstructured":"V\u00e4lim\u00e4ki E. Calculation of Royalties in Compulsory Licensing of Pharmaceutical Patents in Europe \u2013 How Much is Justified? Nordic J Commerc Law. 2011;Special Edition 2011:1\u201327.","journal-title":"Nordic J Commerc Law"},{"key":"956_CR73","unstructured":"World Health Organization. WHO guideline on country pharmaceutical pricing policies, second edition. Geneva. 2020."},{"key":"956_CR74","unstructured":"Global Health Centre. Knowledge Network on Innovation and Access to Medicines research syntheses: pricing Geneva: Graduate Institute; 2024. Available from: https:\/\/www.knowledgeportalia.org\/overview-research-syntheses. Accessed 23 Apr 2024."},{"issue":"2","key":"956_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/heapol\/czt105","volume":"30","author":"TA Nguyen","year":"2015","unstructured":"Nguyen TA, Knight R, Roughead EE, et al. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy Plan. 2015;30(2):267\u201380. https:\/\/doi.org\/10.1093\/heapol\/czt105. (PubMed PMID: 24425694).","journal-title":"Health Policy Plan"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-00956-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T05:52:52Z","timestamp":1750053172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-00956-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-00956-x","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"19 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Belgian Health Care Knowledge Centre (KCE_HSR 2020-50).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data are publicly available and have been described in the KCE report [].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SS, WVD, JL: conceptualisation, funding acquisition, methodology, investigation, formal analysis, writing \u2013 original draft. RJ, LB: data curation, investigation, writing \u2013 review & editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}